GEN

Editas Early Data for CRISPR Therapy EDIT-101 Shows Efficacy “Signals” in Two Patients

Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...
FOX8 Cleveland

Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1

EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and ...
The Scientist

Beckman Coulter Life Sciences: CRISPR 101

CRISPR has increasingly gained popularity in its role with immunotherapy over the years. This short video introduces CRISPR as related to immunotherapy, as well as its capabilities now and into the ...
The Victoria Advocate

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational ...

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through ...
Pharmabiz

Allergan, Editas Medicine begin patient dosing in phase 1/2 trial of CRISPR Medicine AGN-151587 (EDIT-101) to treat LCA10

Allergan plc, a leading global pharmaceutical company, and Editas Medicine, Inc., a leading genome editing company, announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN ...